Imugene Receives FDA Support for Azer-cel CAR-T Therapy Registration Pathway in Lymphoma
核心洞察
Imugene (搜索) secured FDA endorsement for a clear registrational pathway for its allogeneic CAR-T therapy azer-cel, marking the strongest regulatory support to date for the company's lead cell therapy program.
The FDA accepted third-line and later diffuse large B-cell lymphoma (搜索) patients, including those who relapsed after autologous CAR-T therapy, as an appropriate target population for pivotal studies.
Recent Phase 1b trial data demonstrated an 82% overall response rate in CAR-T relapsed DLBCL patients and 83% in CAR-T naïve patients across multiple CD19 (搜索)-positive cancers.
Imugene (搜索) has achieved a significant regulatory milestone after receiving supportive written minutes from the US Food and Drug Administration outlining a clear pathway to Phase 3 registration for its allogeneic CAR-T therapy azercabtagene zapreleucel (azer-cel). The FDA endorsement, delivered following a Type C meeting held on November 21, 2025, represents the strongest regulatory support to date for the company's lead cell therapy program.
FDA Endorses Comprehensive Development Strategy
The FDA confirmed that data from Imugene (搜索)'s ongoing Phase 1b trial, which evaluates azer-cel in combination with augmented lymphodepletion and low-dose IL-2, together with its safety profile, are sufficient to progress toward a pivotal study. The regulator endorsed the company's proposed dosing regimen for the pivotal program, which combines augmented lymphodepletion, a fixed dose of 500 million azer-cel cells, and 14 days of low-dose subcutaneous interleukin-2.
The agency accepted third-line and later diffuse large B-cell lymphoma (搜索), including patients who relapsed following autologous CAR-T therapy, as the target population. This represents a high-need group where treatment choices are limited and real-world outcomes remain poor, with a substantial proportion of patients progressing after currently approved autologous CAR-T products.
Clinical Data Demonstrates Strong Efficacy
Updated data from the ongoing Phase 1b trial show an overall response rate of 82% in CAR-T relapsed DLBCL patients and 83% in CAR-T naïve patients across multiple CD19 (搜索)-positive cancers. The therapy continues to show durable responses, with additional patients maintaining meaningful disease control over time.
The Phase 1b study is an open-label, multi-center trial conducted in the US and Australia that initially enrolled CAR-T relapsed DLBCL patients and has since expanded to include CAR-T naïve patients with a broader range of non-Hodgkin lymphoma (搜索) subtypes, including primary central nervous system lymphoma (搜索), chronic lymphocytic leukemia (搜索)/small lymphocytic lymphoma, marginal zone lymphoma (搜索), Waldenström macroglobulinemia (搜索), and follicular lymphoma (搜索).
Regulatory Pathway and Study Design
The FDA endorsed Imugene (搜索)'s proposal for a single randomized registrational study, using overall response rate with durability to support accelerated approval and progression-free survival for full approval. The control arm is expected to include several investigator-choice therapies, reflecting current standard practice in this setting.
The agency also confirmed that Imugene (搜索)'s Chemistry, Manufacturing, and Controls program is suitable for initiating a registrational study, with only standard refinements required. The FDA requested only standard late-stage refinements to certain analytical methods.
Leadership Perspective and Future Plans
"The alignment across dosing regimen, patient population selection, accelerated approval endpoint strategy and CMC readiness gives us confidence as we continue to design our pivotal study plans," said Imugene (搜索) CEO Leslie Chong. "Combined with our growing clinical data set, we believe azer-cel is well positioned to address high-need patient populations."
The company plans to compile the FDA's written minutes and incorporate the guidance into its pivotal study protocol, operational planning, and broader clinical program strategy. Further meetings with the agency are anticipated as Imugene (搜索) refines the pivotal program and statistical analysis plan.
Rapid enrollment into the CAR-T naïve niche cohort of the Phase 1b trial may open up additional registrational opportunities in other CD19 (搜索)-positive indications, including areas such as primary central nervous system lymphoma (搜索) where no CAR-T products are currently approved.